ClinicalTrials.gg
Active, not recruitingNCT07533903FOCUS-AUSUpdated Nov 6, 2026

Functional Outcomes and Control Using Synchron BCI - Australia

An interventional study of Stentrode in Neurologic Disorder, Neurologic Diseases and MND (Motor Neurone DIsease), sponsored by Synchron, Inc.. Active, not recruiting at 1 site in Australia. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Synchron, Inc. · Not applicable, Interventional, and Other

Updated Nov 6, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Study summary

Functional Outcomes and Control Using Synchron BCI - Australia (FOCUS-AUS)

Read the detailed description

The Synchron BCI motor neuroprosthesis is an implanted brain-computer interface indicated for adults with bilateral upper-limb motor impairment. The Synchron BCI is intended to replace the function of motor neurons by detecting, translating and transmitting motor-related brain signals to restore clinically meaningful control of digital devices.

02

Conditions studied

  • Neurologic Disorder
  • Neurologic Diseases
  • MND (Motor Neurone DIsease)
  • Motor Neuron Disease
  • Motor Neuron Disease, Amyotrophic Lateral Sclerosis
  • Paralysis Arm
  • Paralysis

Keywords

  • ALS
  • BCI
  • Brain Computer Interface
  • MND
  • Upper Limb Paralysis
  • Motor Neurone Disease
03

In context

Nervous System Diseases

757 studies on the registry are indexed under Nervous System Diseases; 218 are open to participants now.

This study's planned enrollment of 10 is below the median of 55 across 495 interventional studies indexed under Nervous System Diseases.

Browse Nervous System Diseases studies →

Lead sponsor

Synchron, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide to participate in the study.
  2. Bilateral upper-limb paresis or Amyotrophic lateral sclerosis (ALS) with bilateral upper limb paresis
  3. The underlying condition causing motor impairment must be to treatment and have been present for a minimum of twelve months.
  4. Aged 21 years or older
  5. greater than 12 months post-implantation
  6. Preserved precentral gyrus assessed using CT
  7. Suitable vascular anatomy assessed using CT venography
  8. Suitable anatomy for subcutaneous pocket creation
  9. Able to undergo anesthesia
  10. Willing and able to comply with requirements, including clinical testing visits and training visits in the home.
  11. Caregiver(s) willing and able to facilitate study visits, including visits at the study site and in the home, and BCI use outside of study visits (e.g. device charging)
  12. Patient and caregiver fluent in English
  13. Suitable home environment for BCI training, including an internet connection

Exclusion criteria

Exclusion Criteria:

  1. Unrealistic expectations regarding the potential benefits of the device.
  2. Active infection or unexplained fever in the 48 hours prior to
  3. Major psychiatric disorder that may adversely impact the participant's safety or study compliance, including severe depression, psychotic features, personality disorder, severe emotional lability, or substance abuse.
  4. Dementia or cognitive dysfunction that would impact the participant's ability to participate in study activities.
  5. Active implanted device (e.g., deep brain stimulator, cardiac defibrillator, pacemaker, vagal nerve stimulator, spinal cord stimulator, diaphragmatic pacer, etc.).
  6. Known allergy to patient-contacting materials included in the implanted device
  7. to angiographic imaging or iodine contrast media.
  8. History of central venous sinus thrombosis.
  9. Recent history of new venous thromboembolic event (in the 6 months prior to implant) or recurrent history of venous thromboembolic disease
  10. Contraindication to antithrombotic therapy.
  11. Participant is at substantially increased risk of infection, including status, recurrent infection, or poorly controlled diabetes mellitus.
  12. Significant risk of non-healing of the subcutaneous pocket incision, including history of chronic non-healing surgical wounds or poorly controlled diabetes mellitus.
  13. Pregnant or breast feeding.
  14. Patients who are currently enrolled in any other clinical trial that would confound interpretation of safety or effectiveness data or may interfere with the ability to meet study requirements.
  15. Any other disease or disorder that could significantly affect participation in the study. Examples may include corrected vision insufficient for viewing computer screens or hearing insufficient for following verbal instructions, which might impact the participant's ability to participate in BCI training and testing.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Prospective, single-arm, open label study

    Single Arm

    Device: Stentrode

Interventions

  • DeviceStentrode

    The Stentrode is an endovascular electrode array that senses electrical signals from the sensorimotor cortices.

06

What researchers measure

Primary outcomes

  1. Device-related serious adverse events resulting in death or permanently increased disability up to 90 days after implant.

    Time frame: 3 Months

Secondary outcomes

  1. Device-related serious adverse events resulting in death or permanently increased disability up to 1 year after implant.

    Time frame: 12 Months

  2. Target vessel patency assessed using CT venography at 90 days and 365 days after implant

    Time frame: 3 Months and 12 Months

  3. Device migration assessed using CT imaging at 90 days and 365 days after implant

    Time frame: 3 Months and 12 Months

Other outcomes

  1. Time in days from implant to device activation

    Time frame: Number of days from implant to device activation, up to 12 months after implant

  2. Stability of recorded Synchron BCI signal up to 1 year after device implant

    Time frame: 12 Months

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2026 to primary completion in Sep 2026, 4 months.

Of 193 interventional studies with no phase under Nervous System Diseases, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 57. This study's 4 months is below that.

Nervous System Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Mar 2027 → Sep 2026 and completion Dec 2027 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2026
First posted
Apr 16, 2026
StartActual
May 22, 2026
Primary completionActual
Sep 22, 2026was Mar 2027
CompletionEst.
Jun 2027was Dec 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 6, 2026
Primary completion
Mar 2027→Sep 22, 2026 (actual)
Nov 6, 2026
Study completion
Dec 2027→Jun 2027
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Recruiting→Active, not recruiting
    Primary completion Mar 2027→Sep 22, 2026 (now actual)
    Study completion Dec 2027→Jun 2027
    + 4 other changes: verification date, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07533903
Lead sponsor
Synchron, Inc.
Responsible party
Sponsor
First posted
Apr 16, 2026
Start date
May 22, 2026
Primary completion
Sep 22, 2026
Completion
Jun 2027 (estimated)
Last update
Nov 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion